PH receives 739K doses of Sinopharm vaccine donated by China | Inquirer News

PH receives 739K doses of Sinopharm vaccine donated by China

By: - Reporter / @KAguilarINQ
/ 06:22 PM August 20, 2021

A shipment of Sinopharm COVID-19 vaccines donated by the Chinese government. Screengrab from PTV

A shipment of Sinopharm COVID-19 vaccine donated by the Chinese government. Screengrab from PTV

MANILA, Philippines — The Philippines on Friday received 739,200 doses of COVID-19 vaccine from Sinopharm donated by the Chinese government.

The vaccines arrived at the Ninoy Aquino International Airport around 5:45 p.m. as shown in a live stream by state media.

Article continues after this advertisement

The shipment is in partial fulfillment of China’s donation of 1 million doses of Sinopharm to the Philippines.

FEATURED STORIES

READ: Duterte receives China’s Sinopharm vaccine

The rest of the vaccines will be delivered to the country on Saturday.

Article continues after this advertisement

China also previously donated 1 million doses of the Sinovac COVID-19 vaccine to the country.

Article continues after this advertisement

All in all, the Philippines already received over 47.2 million COVID-19 vaccine doses since February.

Meanwhile, over 12.8 million individuals have been fully vaccinated against COVID-19 as of August 18, with nearly 30 million doses already administered.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: China, coronavirus Philippines, Sinopharm

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.